Publications
27 results found
Le Calvez K, Mauricaite R, Williams M, 2022, FIRST LINE TREATMENT OF ADULT GLIOBLASTOMA PATIENTS IN ENGLAND 2103-2018 FROM THE GLIOCOVA PROJECT, Publisher: OXFORD UNIV PRESS INC, Pages: 16-16, ISSN: 1522-8517
Kanso N, Mauricaite R, Le Calvez K, et al., 2022, THE COST OF TREATING ADULT GLIOBLASTOMA PATIENTS IN ENGLAND, Annual Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 2-2, ISSN: 1522-8517
Caldano M, Droney J, Mauricaite R, et al., 2022, WHERE DO PEOPLE WITH PRIMARY MALIGNANT BRAIN TUMOURS DIE? A NATIONAL COHORT STUDY IN ENGLAND, USING GLIOCOVA DATA, Publisher: OXFORD UNIV PRESS INC, Pages: 1-1, ISSN: 1522-8517
Pakzad-Shahabi L, Tallant J, Le Calvez K, et al., 2022, CAPABLE - ASSESSING THE PATIENT GENERATED INDEX METHODOLOGY IN HIGH GRADE GLIOMA PATIENTS AND CAREGIVERS, Annual Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 5-5, ISSN: 1522-8517
Mauricaite R, Le Calvez K, Brodbelt A, et al., 2022, GLIOCOVA: PREDICTORS OF POST-OPERATIVE COMPLICATIONS, 30 DAY MORTALITY AND READMISSION AFTER FIRST SURGICAL INTERVENTION IN BRAIN TUMOUR PATIENTS IN ENGLAND BETWEEN 2013-2018, Annual Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 8-8, ISSN: 1522-8517
Kanso N, Le Calvez K, Mauricaite R, et al., 2022, THE COST OF INPATIENT CARE FOR ADULT PRIMARY BRAIN TUMOUR PATIENTS IN ENGLAND, 17th Meeting of the European-Association-of-Neuro-Oncology, Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517
Pakzad-Shahabi L, Tallant J, Le Calvez K, et al., 2022, CaPaBLE-Assessing the Patient Generated Index Methodology in High Grade Glioma Patients and Caregivers, Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517
Le Calvez K, Mauricaite R, Williams M, 2022, A DESCRIPTION OF INPATIENT ADMISSIONS OF ADULT GLIOBLASTOMA PATIENTS IN ENGLAND 2103-2018 FROM THE GLIOCOVA PROJECT, 17th Meeting of the European-Association-of-Neuro-Oncology, Publisher: OXFORD UNIV PRESS INC, ISSN: 1522-8517
Chen J, Sinclair G, Rozati H, et al., 2022, Improving on whole-brain radiotherapy in patients with large brain metastases: a planning study to support the AROMA clinical trial, Radiotherapy and Oncology, Vol: 170, Pages: 176-183, ISSN: 0167-8140
PURPOSE: To develop a novel dose-escalated volumetric modulated arc therapy (VMAT) strategy for patients with single or multiple large brain metastases which can deliver a higher dose to individual lesions for better local control (LC), and to compare dosimetry between whole brain radiotherapy (WBRT), hippocampal-sparing whole brain radiotherapy (HS-WBRT) and different VMAT-based focal radiotherapy approaches. METHODS AND MATERIALS: We identified 20 patients with one to ten brain metastases and at least one lesion larger than 15 cm3 who had received WBRT as part of routine care. For each patient, we designed and evaluated five radiotherapy treatment plans, including WBRT, HS-WBRT and three VMAT dosing models. A dose of 20 Gy in 5 fractions was prescribed to the whole brain or target volumes depending on the plan, with higher doses to smaller lesions and dose-escalated inner planning target volumes (DE-iPTV) in VMAT plans, respectively. Treatment plans were evaluated using the efficiency index, mean dose and D0.1cc to the target volumes and organs at risk. RESULTS: Compared with WBRT, VMAT plans achieved a significantly more efficient dose distribution in brain lesions, especially with our DE-iPTV model, while minimising the dose to the normal brain and other organs at risks (OARs) (p < 0.05). CONCLUSIONS: VMAT plans obtained higher doses to brain metastases and minimised doses to OARs. Dose-escalated VMAT for larger lesions allows higher radiotherapy doses to be delivered to larger lesions while maintaining safe doses to OARs.
Sinclair H, Le Calvez K, Chen J, et al., 2021, Estimating population-based incidence of brain metastases–a comprehensive incident cohort study, BNOS 2021 Meeting, Publisher: Oxford University Press, Pages: iv21-iv21, ISSN: 1522-8517
Mauricaite R, Le Calvez K, Williams M, 2021, GLIOCOVA: TREATMENT AND HOSPITAL ADMISSIONS FOR PATIENTS WITH GBM IN ENGLAND, Annual Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 13-13, ISSN: 1522-8517
Dadhania S, Pakzad-Shahabi L, Le Calvez K, et al., 2021, BRAINWEAR: LONGITUDINAL, OBJECTIVE ASSESSMENT OF PHYSICAL ACTIVITY IN 42 HIGH GRADE GLIOMA (HGG) PATIENTS, Annual Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 3-3, ISSN: 1522-8517
Dadhania S, Pakzad-Shahabi L, Mistry S, et al., 2021, BRAINWEAR: LONGITUDINAL, OBJECTIVE ASSESSMENT OF PHYSICAL ACTIVITY IN 42 HGG PATIENTS, Publisher: OXFORD UNIV PRESS INC, Pages: 13-13, ISSN: 1522-8517
- Author Web Link
- Cite
- Citations: 1
Pakzad-Shahabi L, Cherrington C, Brassil N, et al., 2021, PATIENT AND PUBLIC INVOLVEMENT TO DEFINE PATIENT-CENTRED OUTCOMES FROM NATIONAL CANCER DATASETS, Publisher: OXFORD UNIV PRESS INC, Pages: 41-41, ISSN: 1522-8517
Mauricaite R, Le Calvez K, Brodbelt A, et al., 2021, GLIOCOVA: DEFINING PATIENT SAFETY EVENTS FOR BRAIN TUMOUR PATIENTS UNDERGOING NEUROSURGERY, Publisher: OXFORD UNIV PRESS INC, Pages: 16-16, ISSN: 1522-8517
Mauricaite R, Le Calvez K, Droney J, et al., 2021, EXPLORING END-OF-LIFE CARE IN THE GLIOCOVA NATIONAL BRAIN TUMOUR PATIENT COHORT, Publisher: OXFORD UNIV PRESS INC, Pages: 43-43, ISSN: 1522-8517
Williams M, Mi E, Le Calvez K, et al., 2021, Estimating the risk of death from COVID-19 in adult cancer patients, Clinical Oncology, Vol: 33, Pages: e172-e79, ISSN: 0936-6555
AIMS: During the coronavirus disease 2019 (COVID-19) pandemic, organisations have produced management guidance for cancer patients and the delivery of cytotoxic chemotherapy, but none has offered estimates of risk or the potential impact across populations. MATERIALS AND METHODS: We combined data from four countries to produce pooled age-banded case fatality rates, calculated the sex difference in survival and used data from four recent studies to convert case fatality rates into age/sex-stratified infection fatality rates (IFRs). We estimated the additional risk of death in cancer patients and in those receiving chemotherapy. We illustrate the impact of these by considering the impact on a national incident cancer cohort and analyse the risk-benefit in some clinical scenarios. RESULTS: We obtained data based on 412 985 cases and 41 854 deaths. The pooled estimate for IFR was 0.92%. IFRs for patients with cancer ranged from 0 to 29% and were higher in patients receiving chemotherapy (0.01-46%). The risk was significantly higher with age and in men compared with women. 37.5% of patients with a new diagnosis of cancer in 2018 had an IFR ≥5%. Survival benefits from adjuvant chemotherapy ranged from 5 to 10% in some common cancers, compared with the increased risk of death from COVID-19 of 0-3%. CONCLUSIONS: Older male patients are at a higher risk of death with COVID-19. Patients with cancer are also at a higher risk, as are those who have recently received chemotherapy. We provide well-founded estimates to allow patients and clinicians to better balance these risks and illustrate the wider impact in a national incident cohort.
Spencer K, Hall P, Henry A, et al., 2020, Fractionation and early mortality in palliative radiotherapy across the English NHS, Publisher: ELSEVIER IRELAND LTD, Pages: S285-S286, ISSN: 0167-8140
Macnair A, Sharkey A, Le Calvez K, et al., 2020, The Trigger Project: The Challenge of Introducing Electronic Patient-Reported Outcome Measures Into a Radiotherapy Service, CLINICAL ONCOLOGY, Vol: 32, Pages: E76-E79, ISSN: 0936-6555
- Author Web Link
- Cite
- Citations: 5
Sharkey A, MacNair A, Le Calvez K, et al., 2019, The Trigger project: Introducing electronic patient reported outcome measures into radiotherapy services, National Cancer Research Institute and Leader in Healthcare Conferences
BackgroundPatients receiving pelvic radiotherapy can experience long term gastrointestinal side effects post-radiotherapy. The Trigger project identifies patients experiencing symptoms of radiation-related bowel toxicity using the ALERT-B questionnaire, and directs them to the appropriate clinician.Trigger is a service evaluation project, aiming to prove the utility of electronic patient reported outcome measures (PROMs), and to demonstrate the feasibility of a low-resource project as a model for collecting PROMs. It is a collaboration between Macmillan Cancer Support, the Royal College of Radiologists, and three NHS Trusts: Velindre, Imperial College Healthcare and Brighton and Sussex University Hospitals.MethodPatients register on the Trigger website, hosted by My Clinical Outcomes, and receive periodic emails to complete the short ALERT-B questionnaire electronically, to screen for long-term bowel symptoms which could have been caused by pelvic radiotherapy. If answering “yes” to any of the questions, patients are directed to appropriate services. Six months following the completion of their radiotherapy, patients are sent a separate questionnaire to evaluate the utility of the project. Results336 patients registered in first the 9 months across the 3 sites. Patients with a range of different cancers signed up: anal (2%), bladder (1%), prostate (87%), rectal (4%) and gynaecological (6%). 43 patients (of 65 eligible (uptake 66%)) have answered their 6-month post treatment questionnaire thus far, and 72% answered "yes" to at least one of the ALERT-B questions. 85% of responding patients reported they found the Trigger project helpful.ConclusionThese promising results show that electronic PROMS can be introduced in radiotherapy departments using a low resource model. The Trigger project works as a feasibility model, showing patients engage with electronic PROMs projects, and find them useful. PROMs for other tumour types could be collected in a
Sharkey A, MacNair A, Le Calvez K, et al., 2019, The Trigger project: Introducing electronic patient reported outcome measures into radiotherapy services, Cancer Conference of the National-Cancer-Research-Institute (NCRI), Publisher: NATURE PUBLISHING GROUP, Pages: 26-26, ISSN: 0007-0920
Le Calvez K, Treasure P, Williams M, 2019, Using surgical and oncology workload to plan brain tumour trial recruitment in England, Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 11-11, ISSN: 1522-8517
IntroductionAccess to clinical trials is a common request for patients with brain tumours. However, opening clinical trials requires additional work per centre opened. We have previously shown that surgical and oncology workload varies between centres, and fluctuates over time. There is a trade-off between offering access to clinical trials and increasing costs associated with opening trials in centres that treat few patients.MethodsWe used two separate datasets from England covering 3 years – one for neurosurgical workload and one for radiotherapy. We only included adult patients and calculated cumulative proportions of the malignant primary brain tumour population (C71) by number of centres. We investigated stability by checking how many patients would have to be added/ removed from a centre to change their rank.ResultsThere were 7061 surgical and 5060 radiotherapy patients. To capture 25% of patients, we would need to open trials in 4 surgical/5 radiotherapy centres; for 50%, 9 surgical/ 13 radiotherapy centres; for 75%, 16 surgical/ 24 radiotherapy centres. Centre rank was fluid: adding 16 surgical/9 radiotherapy patients would change the rank of a centre.DiscussionThese are the first data to allow for rational planning of trials in brain tumour patients. We have shown that we can reach 75% of the brain tumour population by opening trials in ~50% of surgical and radiotherapy centres. Centre rank alters over year, so we should be cautious about being too prescriptive. Nonetheless, these data should allow some rational planning of trial centre inclusion.
Shahabi L, Le Calvez K, Dadhania S, et al., 2019, REAL-WORLD EXPERIENCE WITH TEMOZOLOMIDE & SATIVEX IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS, Meeting of the British-Neuro-Oncology-Society (BNOS), Publisher: OXFORD UNIV PRESS INC, Pages: 13-14, ISSN: 1522-8517
Spencer K, Le Calvez K, Hall P, et al., 2019, Fractionation and early mortality in palliative radiotherapy: Insights from the national radiotherapy dataset, Publisher: ELSEVIER SCIENCE LONDON, Pages: E14-E14, ISSN: 0936-6555
- Author Web Link
- Cite
- Citations: 1
Pakzad-Shahabi L, Soni S, Le Calvez K, et al., 2019, Response rates to Quality of Life questionnaires over time (why we need the CaPaBLE study)
Kroupa P, Morton C, Le Calvez K, et al., 2019, Assessing K-Nearest Neighbours algorithm for simple, interpretable time-to-event survival predictions over a range of simulated datasets, 32nd IEEE International Symposium on Computer-Based Medical Systems (IEEE CBMS), Publisher: IEEE, Pages: 367-372, ISSN: 2372-9198
Phelip J, Porte F, Setton M, et al., 2016, MANAGEMENT OF METASTATIC COLORECTAL CANCER PATIENTS: A METHODOLOGICAL APPROACH TO IDENTIFY TREATMENT LINES, Publisher: ELSEVIER SCIENCE INC, Pages: A756-A757, ISSN: 1098-3015
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.